Autologous dendritic cells (DCs) transfected with mRNA encoding prostate-specific antigen
(PSA) are able to stimulate potent, T cell–mediated antitumor immune responses in vitro. A …

Polyvalent cancer vaccines targeting the entire antigenic spectrum on tumor cells may
represent a superior therapeutic strategy for cancer patients than vaccines solely directed …

Here, we present results from a clinical trial employing a new vaccination method using
dendritic cells (DCs) transfected with mRNA from allogeneic prostate cancer cell lines …

Although immunological tolerance to self Ags represents an important mechanism to prevent
normal tissue injury, there is growing evidence that tolerance to tumor Ags, which often …

Bone marrow‐derived dendritic cells (DCs) are the most potent antigen‐presenting cells
capable of activating naïve T cells. Loading DCs ex vivo with tumor antigens can stimulate …

Dendritic cells (DCs) are “professional” antigen‐presenting cells capable of stimulating T‐
cell proliferation and cytotoxicity when loaded with and presenting specific antigens …

Prostate stem cell antigen (PSCA) and prostate‐specific antigen (PSA) are overexpressed in
most prostate cancers. PSCA‐and PSA‐derived, HLA‐A2 binding peptides are specific …

Abstract BACKGROUND A phase II trial was conducted to assess the efficacy of infusions of
dendritic cells (DC) and two HLA‐A2‐specific PSMA peptides (PSM‐P1 and‐P2). This report …

Abstract BACKGROUND A phase II trial, involving infusions of autologous dendritic cells
(DC) and two human histocompatibility antigen (HLA‐A2)‐specific prostate‐specific …

Background Clinical benefit of cellular immunotherapy has been shown in patients with
castration-resistant prostate cancer (CRPC). We investigated the immunological response …